Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Depreciation and Depletion (2021 - 2024)

Trinity Biotech's Depreciation and Depletion history spans 4 years, with the latest figure at $317000.0 for Q4 2024.

  • On a quarterly basis, Depreciation and Depletion rose 15750.0% to $317000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $416260.0, a 36.76% decrease, with the full-year FY2025 number at $1.3 million, up 92.44% from a year prior.
  • Depreciation and Depletion hit $317000.0 in Q4 2024 for Trinity Biotech, up from $260.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for TRIB hit a ceiling of $655649.0 in Q2 2023 and a floor of $47.0 in Q2 2022.
  • Historically, Depreciation and Depletion has averaged $165542.8 across 4 years, with a median of $2000.0 in 2023.
  • The widest YoY moves for Depreciation and Depletion: up 1394897.87% in 2023, down 99.96% in 2023.
  • Tracing TRIB's Depreciation and Depletion over 4 years: stood at $146000.0 in 2021, then soared by 210.27% to $453000.0 in 2022, then tumbled by 99.56% to $2000.0 in 2023, then skyrocketed by 15750.0% to $317000.0 in 2024.
  • Business Quant data shows Depreciation and Depletion for TRIB at $317000.0 in Q4 2024, $260.0 in Q3 2024, and $98836.0 in Q2 2024.